ACAAI 2017 Annual Scientific Meeting
Precision Medicine in Allergy Practice:
A Rich History. A Strong Future.
October 26-30, 2017
Submission Deadline: JUNE 15, 2017
Author Financial Disclosures Deadline: JUNE 15, 2017
GENERAL ABSTRACT SUBMISSION POLICIES AND PROCEDURES:
The College invites you to submit an abstract for the 2017 Annual Scientific Meeting in Boston, Massachusetts, October 26-30, 2017. The theme of the meeting is: Precision Medicine in Allergy Practice: A Rich History. A Strong Future.
The deadline for abstract submission is 11:59 PM (CDT) on June 15, 2017. Abstracts must be submitted electronically via the online form, and they must be complete, including the author listing. ACAAI will not accept any abstracts or abstract changes after the submission deadline. Abstract changes include: changes to title or body, author additions, revised author names, and/or revised author listing. This deadline applies to ALL abstracts.
There is a $60 non-refundable fee for each abstract submission. Payment does not guarantee that the abstract will be accepted. Payment must be made by credit card (Visa, MasterCard or American Express). Purchase orders and checks will not be accepted.
- ACAAI only accepts original abstracts. Abstracts previously accepted and/or published by other organizations should not be submitted. If an abstract submitted to ACAAI is accepted for programming and/or publication by another organization prior to its acceptance by ACAAI, it must be withdrawn from consideration for the ACAAI Annual Meeting. An individual can only be the presenting author on one abstract. If submitting more than one abstract, you will have to identify co-authors as the presenter(s) for other abstracts.
- As the submitter, you will be the main contact person for the abstract, and as such, it will be your responsibility to make sure the other authors are informed of any communications from ACAAI regarding the abstract (including requests from the Abstract Review Subcommittee for additional information, disposition and placement decision, missing disclosures, etc.). If you are unwilling or unable to function in this capacity, please designate someone else as the contact person.
- It is the responsibility of the submitting author to ensure accuracy of content, spelling and author information, including listing order. Abstracts are directly exported from the submission database for publication.
- Please review your submission carefully to make sure that all appropriate data and all authors are listed and in the correct order. Absolutely no changes to body copy, data or authors will be accepted after the submission deadline of June 15, 2017, 11:59 pm (CDT).
If the Presenting Author wishes to withdraw his/her abstract from the Annual Meeting program, a written request must be submitted to email@example.com by August 25, 2017. Any abstract withdrawn after that date cannot be assured removal from the 2017 ACAAI Annual Scientific Meeting Program Guide or the November issue of Annals.
Abstract Author Disclosure of Financial Relationships
Abstracts may be submitted by fellows, members and non-members of the College. Employees of pharmaceutical or medical device companies or other ACCME-defined commercial interests are prohibited from participating as an author or presenter of an oral abstract; however, they may participate as an author or presenter for the poster session.
An ACCME-defined commercial interest is, “any entity producing, marketing, reselling or distributing healthcare goods or services used on, or consumed by, patients.”
All authors must complete the online Disclosure of Financial Relationships by June 15, 2017.
Disclosure of relevant financial relationships includes the commercial interest name, the role played, and what was received.
- Type of relationships include: employee, consultant/advisor, speaker, supported/contracted research, patent holder/royalty IPR, board member (for profit organizations), author/editor
- Types of financial incentives received include: salary, ownership interests (stocks or other ownership interests, excluding diversified mutual funds), consulting fees, honorarium, grants, royalty, intellectual property rights, or other financial benefit
The ACCME has not set a minimum dollar amount for relationships to be considered relevant and does not use the term significant to describe financial relationships. Inherent in any amount is the incentive to maintain or increase the value of the relationship.
All abstracts must be devoid of commercial bias. Trade names should not be used in referencing drugs, devices or instrumentation. Any medications or other substances referred to in the presentation material should be identified by their generic name or description. Trade name violations/commercial bias will result in below average scores. Failure to disclose financial relationships with ACCME-defined commercial interests will prohibit an author/presenter from participating in oral and poster sessions.
HERE'S WHAT YOU WILL NEED TO SUBMIT FOR EACH AUTHOR:
- You must list your authors in the order in which they should appear in the abstract. If you are the presenting author, your name needs to be listed first
- First Name, Middle Initial and Last Name
- Company/Institution Name
- City, State and Country (where employed)
- Author Email
- All authors listed on your abstract will receive an email with a link for completing their disclosure. Please make sure they respond; all authors listed on your abstract are REQUIRED to disclose and it will be your responsibility as the Submitter and/or Presenting Author to follow-up with the other authors to make sure the disclosures have been submitted.
- Your abstract WILL NOT be reviewed unless all listed authors have: a) approved the submission of the abstract for consideration for presentation at the ACAAI 2017 Annual Meeting; and b) completed and their online disclosure by June 15, 2017.
ORGANIZATION OF ABSTRACT BODY:
Each abstract should contain:
- Introduction: A brief introduction indicating the reason for the study
- Methods: A description of the methods used to evaluate the study (do not include laboratory techniques)
- Results: Specific data necessary to evaluate the abstract (Statements such as “data will be discussed at the presentation” are grounds for refusal of the abstract)
- Conclusion: A brief conclusion indicating the significance of the results in terms of what was originally designed. The results should occupy 1/2 to 2/3 of the abstract. DO NOT mention the institution where the work was performed in the body or title of the abstract.
Be sure to use the words “Introduction, Methods, Results, Conclusion” in the body of your abstract to indicate the start of each new section. The abstract title and author information should not be included in the body of the abstract. If you are submitting a Case Report, you may use section titles of "Case Presentation, Discussion, Rationale, Background" etc. You are also able to use "Introduction, Methods, Results, Conclusion" where applicable.
Best results are achieved copying and pasting directly from a Word document. Please make sure that you use the "Insert Symbols" feature in Word for any mathematical, Latin or scientific expressions. If you are entering the copy directly onto the Abstract Form, you must use the “Symbols” icon to ensure your result is displayed accurately. You will also need to use the "Paste from Word" icon which is displayed right next to the "Undo" icon on the text editor shown above. Always verify that your information is correct prior to submitting by selecting "Print Preview."
There is a limit of 15 words for the title and 250 words for the body of your abstract submission.
Capitalize only the first letter of each word of the title. Do not use formatting tags in the title. The title will be formatted automatically by the system at the time of print production. Abbreviations must not be used in the title.
All abstracts must be devoid of commercial bias. Trade names should not be used in referencing drugs, devices or instrumentation. Any medications or other substances referred to in the presentation material should be identified by their generic name or description. Trade name violations/commercial bias will result in below average scores.
Use of Figures
You may add one figure to your abstract, however, it is recommended that results be shown in narrative form, since figure formats may be compromised in publication. The figure must be submitted as a jpg file and cannot exceed 500kb.
If the abstract is accepted for presentation at the 2017 ACAAI Annual Meeting, the submitting author will be notified via email in late July. Only the submitting author will be notified of abstract programming. Please make sure all contact information is accurate. The notification will include: 1) placement decision; 2) date and time of session; and 3) format of presentation (oral or poster). Abstracts scheduled for presentation will be grouped by topic, numbered and listed in the program and published in the Annals abstract supplement. The decision of the ACAAI Abstract Review Subcommittee regarding acceptance and presentation of abstracts is final.
All authors who will be attending the Annual Meeting must register online for the meeting and pay any applicable registration fees. The meeting registration site will open in mid-July.
For your convenience, all accepted posters for the 2017 ACAAI Annual Meeting will be displayed electronically. Complete details regarding the electronic posters will be sent to the submitting author of accepted abstracts at the end of August.
Submit an Abstract